Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Cited by (294)

Items 101–200 of 294

1. Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
   Shijia Zhang, Daniel Fellows Pease, Amit A. Kulkarni, Manoj Kumar, Ryan Shanley, Beibei Xu, Shilvi P Joshi, Manish Ramesh Patel · 2021 · Clinical Medicine Insights Oncology
2. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
   Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su, Junling Yang · 2023 · International Journal of Oncology
3. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
   Cornelis Bisschop, Thijs T. Wind, Christian U. Blank, Rutger H.T. Koornstra, Ellen Kapiteijn, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Mathilde Jalving, Geke A.P. Hospers · 2019 · Journal of Immunotherapy
4. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
   Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, Cinzia Baldessari, Camillo Porta, Federica Iannuzzi, Umberto Basso, Sarah Scagliarini, Paolo Andrea Zucali, Luca Galli et al. · 2020 · Clinical Genitourinary Cancer
5. Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
   Neta Bar-Hai, Guy Ben‐Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Shapira‐Frommer, Nethanel Asher · 2023 · Cancers
6. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
   Jordi Remón, Noemı́ Reguart, Édouard Auclin, Benjamin Besse · 2019 · Journal of Thoracic Oncology
7. Clinical burden of immune checkpoint inhibitor-induced pneumonitis
   Koji Sakamoto, Jun Fukihara, Masahiro Morise, Naozumi Hashimoto · 2020 · Respiratory Investigation
8. Do Immune-Related Adverse Events Correlate with Response to Immune Checkpoint Inhibitors?
   Khalil Saleh, Nadine Khalifé-Saleh, Hampig Raphaël Kourié · 2019 · Immunotherapy
9. Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients
   Kota Iwahori, Takeshi Uenami, Yukihiro Yano, Toshihiko Ueda, Mari Tone, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Takayuki Shiroyama, Kotaro Miyake et al. · 2022 · Scientific Reports
10. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
    Kazuo Kobayashi, Yusuke Iikura, Makoto Hiraide, Takashi Yokokawa, Takeshi Aoyama, Sari Shikibu, Koki Hashimoto, Kenichi Suzuki, Hitoshi Sato, Erika Sugiyama et al. · 2020 · In Vivo
11. Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
    Kana Ono, Hirotaka Ono, Yukihiro Toi, Jun Sugisaka, Mari Aso, Ryohei Saito, Sachiko Kawana, Tomoiki Aiba, Tetsuo Odaka, Suguru Matsuda et al. · 2021 · Cancer Medicine
12. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Takafumi Yamamoto, Takanori Ito, Tetsunari Hase, Masatoshi Ishigami, Kazuyuki Mizuno, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Hirofumi Shibata et al. · 2021 · Cancer Investigation
13. Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma
    Cecilia Monge, Changqing Xie, Seth M. Steinberg, Tim F. Greten · 2021 · Journal of Hepatocellular Carcinoma
14. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
    Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong · 2021 · BMC Cancer
15. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
    Jordyn F. Silverstein, Francis Wright, Michelle Wang, Arabella Young, Daniel Kim, Kimberly de Dios, Sam Brondfield, Zoe Quandt · 2023 · The Oncologist
16. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
    Matthew J. Townsend, Mofei Liu, Anita Giobbie‐Hurder, Jordan Sack, Nicole R. LeBoeuf, Frank Stephen Hodi, Julia Y. McNabb-Baltar, Shilpa Grover · 2023 · Journal of the National Comprehensive Cancer Network
17. Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
    Yuchen Huang, Wananqi Ma, Dongsheng Wu, Mengyuan Lyu, Quan Zheng, Tengyong Wang, Jian Zhou, Chengwu Liu · 2024 · Translational Lung Cancer Research
18. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
    Marta Dudzińska, Michał Szczyrek, Kamila Wojas‐Krawczyk, Joanna Świrska, Izabela Chmielewska, Agnieszka Zwolak · 2020 · Cancers
19. Immunotherapy Toxicities
    Katherine G. Sanchez, David B. Page, Walter John Urba · 2019 · Surgical Oncology Clinics of North America
20. Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity
    Romana Elisabeth Wass, Maximilian Johannes Hochmair, Bernhard Kaiser, Brane Grambozov, Petra Feurstein, Gertraud Weiß, Raphaela Moosbrugger, Felix Sedlmayer, Bernd Lamprecht, Michael Studnicka et al. · 2022 · Cancers
21. Correlation between immune‑related adverse events and treatment efficacy of anti‑PD1 immunotherapy in patients with esophageal squamous cell carcinoma
    Ruijie Cao, Chensi Wu, Yalei Lv, Shuo Xu, Cuizhen Li, Fei Yin, Jing Li · 2022 · Oncology Letters
22. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
    Huilin Xu, Ximing Xu, Wei Ge, Jin-Ju Lei, Dedong Cao · 2020 · Therapeutic Advances in Medical Oncology
23. Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Yu Ling Zhou, Haizhu Chen, Le Min Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou, Yuankai Shi · 2023 · Immunotherapy
24. Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
    Xiaoyu Liu, Na Hao, Shuangning Yang, Jieyao Li, Liping Wang · 2023 · Frontiers in Oncology
25. Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer
    George Raynes, Mark D. Stares, Samantha Low, Dhania Haron, Hussain Sarwar, Dhruv Abhi, Colin Barrie, Barry J. A. Laird, Caledonian Cachexia Collaborative, Iain Phillips et al. · 2023 · Cancers
26. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors
    Moshe Chaim Ornstein, Cassandra M. Calabrese, Laura S. Wood, Elizabeth Kirchner, Pam Profusek, Kimberly D Allman, Allison M. Martin, Apostolos Kontzias, Petros D. Grivas, Jorge Alberto Garcia et al. · 2019 · Clinical Genitourinary Cancer
27. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    Izabela Chmielewska, Marta Dudzińska, Michał Szczyrek, Joanna Świrska, Kamila Wojas‐Krawczyk, Agnieszka Zwolak · 2021 · PLoS ONE
28. Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer
    Olivier Humbert, Matteo Bauckneht, Jocelyn Gal, Marie Paquet, David Chardin, David Rener, Aurélie Schiazza, Carlo Genova, Renaud Schiappa, Lodovica Zullo et al. · 2022 · European Journal of Nuclear Medicine and Molecular Imaging
29. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature
    Christopher Hino, Kevin Nishino, Bryan Pham, Won Jin Jeon, Michael Nguyen, Huynh Le Cao · 2022 · Frontiers in Immunology
30. Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
    Xiaoxiao Ge, Weiping Jiang, Hongqing Li, Yanxu Wu, Xiangyang Li, Shaohua Cui · 2023 · Cancer Medicine
31. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors
    Zi Wan, Jiangyuan Huang, Xiaojie Ou, Shuang Lou, Jianji Wan, Zhu Shen · 2024 · Anais Brasileiros de Dermatologia
32. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors
    Ryan G. Holstead, Baskoro Kartolo, Wilma M. Hopman, Tara D. Baetz · 2021 · Melanoma Research
33. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis
    Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Hiroshi Yamamoto, Tomonobu Koizumi, Masayuki Hanaoka · 2021 · Oncology
34. Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
    Yanyun Shen, Yunfeng Chen, Duoqin Wang, Zhidong Zhu · 2020 · Medicine
35. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database
    Ruth Percik, Yair Liel, Damien Urban, Jair Bar, Eytan Ben‐Ami, Muhammad Abu Tailakh · 2021 · Acta Oncologica
36. Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
    Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, YooHyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Akihiro Miura et al. · 2022 · Cancer Management and Research
37. Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
    Maria V. Deligiorgi, Mihalis I. Panayiotidis, Dimitrios T. Trafalis · 2020 · Immunotherapy
38. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
    Yoshiyasu Kono, Yasuhiro Choda, Masahiro Marshall Nakagawa, Koji Miyahara, Michihiro Ishida, Tetsushi Kubota, Keiji Seo, Tetsu Hirata, Yuka Obayashi, Tatsuhiro Gotoda et al. · 2021 · Targeted Oncology
39. Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
    Matteo Silberg, Laura‐Maria Krabbe, Martin Bögemann, Andres Jan Schrader, Karl H. Tully, Katrin Schlack · 2024 · Clinical Genitourinary Cancer
40. Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
    Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, Anna Bidas, Jolanta Dobrzańska, Aleksandra Grela-Wojewoda, Agnieszka Roman, Daria Tusień-Małecka, Jerzy Andrzej Walocha, Paweł Blecharz et al. · 2024 · BMC Cancer
41. The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
    Fausto Omero, Desirèe Speranza, Giuseppe Murdaca, Mariacarmela Cavaleri, Mariapia Marafioti, Vincenzo Cianci, Massimiliano Berretta, Marco Casciaro, Sebastiano Gangemi, Mariacarmela Santarpía · 2025 · Biomolecules
42. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study
    Akihiko Sano, Makoto Sohda, Nobuhiro Nakazawa, Yasunari Ubukata, Kengo Kuriyama, Akiharu Kimura, Norimichi Kogure, Hisashi Hosaka, Atsushi Naganuma, Masanori Sekiguchi et al. · 2022 · BMC Cancer
43. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer
    Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, 昭久 藤田, Hideki Sato · 2021 · Cancer Control
44. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
    Machiko Kawahira, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, Masaru Yamashita, Takuro Kanekura, Shiho Arima et al. · 2022 · PLoS ONE
45. Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
    Tri Le, John Dorrance Minna, David E. Gerber · 2019 · Journal of Thoracic Oncology
46. Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
    Jordi Remón, Laura Esteller, Álvaro Taus · 2019 · Cancer Management and Research
47. Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
    Robert D. Schouten, Lucie Egberink, Mirte Muller, Cornedine Jannette de Gooijer, Erik D. van Werkhoven, Michel M. van den Heuvel, Paul Baas · 2020 · Translational Lung Cancer Research
48. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)
    Shotaro Ito, Hajime Asahina, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Satoshi Oizumi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai et al. · 2021 · Lung Cancer
49. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases
    Michael Zhang, Adrian John Rodrigues, Erqi Liu Pollom, Iris C. Gibbs, Scott G. Soltys, Steven L. Hancock, Joel W. Neal, Sukhmani Kaur Padda, Kavitha J. Ramchandran, Heather A. Wakelee et al. · 2021 · Journal of Neuro-Oncology
50. Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction
    Yi Li, Yue Zang, Tianda Fan, Zhaochen Li, Anzi Li, Wei Lv, Qingqing Wang, Qinglan Li, Yuanyuan Li, Quan Li et al. · 2022 · Computational and Structural Biotechnology Journal
51. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
    Angela E. Alnemri, Sruti Tekumalla, Annie E. Moroco, Ioannis Athanasios Vathiotis, Madalina Tuluc, Stacey Gargano, Tingting Zhan, David M. Cognetti, Joseph Curry, Athanassios E. Argiris et al. · 2024 · Cancer Medicine
52. Clinical characteristics and influencing factors of anti-PD-1/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases
    Xitong Cheng, Jierong Lin, Bitao Wang, Shunming Huang, Maobai Liu, Jing Yang · 2024 · Scientific Reports
53. Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
    Yuki Akazawa, Aki Yoshikawa, Masaki Kanazu, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori · 2022 · Thoracic Cancer
54. Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
    Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi et al. · 2024 · Cancer Medicine
55. Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis
    Karin Tina Mayer, Wibke Briese, Johannes Blieninger, Peter Brossart, Savita Bisht, Georg Feldmann · 2021 · Oncology Research and Treatment
56. Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy
    Tomoki Maetani, Toka Hamaguchi, Takafumi Nishimura, Satoshi Marumo, Motonari Fukui · 2021 · Internal Medicine
57. Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)
    Hirotsugu Kenmotsu, Yoshinobu Saito, Kiichiro Ninomiya, Shinya Uematsu, Burak Akdemir, Ayako Fukui, Ryo Koto, Masakazu Fujiwara, Chikako Iwao, Hiroshi Kitagawa et al. · 2025 · Journal of Thoracic Oncology
58. Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
    Yi-Luen Shen, Chia‐I Shen, Chi‐Lu Chiang, Hsu-Ching Huang, Kun‐Ta Chou, Chao‐Hua Chiu, Yuh‐Min Chen, Yung‐Hung Luo · 2022 · Frontiers in Medicine
59. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
    Yacki Hayashi‐Tanner, Peter James Polewski, Mamatha Gaddam, Nancy R. Fisher, Attila J. Kovacs, David E. Marinier · 2022 · Journal of Geriatric Oncology
60. The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials
    Daniele Robesti, Luigi Nocera, Federico Belladelli, Julianne G. Schultz, Giuseppe Fallara, Laura Marandino, Daniele Raggi, Francesco Montorsi, Pavlos Msaouel, Andrea Necchi et al. · 2023 · British Journal of Urology
61. Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
    Alejandro Ríos-Hoyo, Jiawei Dai, T. Noel, Kim Blenman, T. Park, Lajos Pusztai · 2025 · ESMO Open
62. Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review
    Omar Abdihamid, Abeid Athman, Tibera K. Rugambwa · 2021 · ecancermedicalscience
63. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness
    Susana Cortijo‐Cascajares, Ana Cristina Cercós-Lletí, Sara Ortiz-Pérez, José Manuel Caro Teller, José Miguel Ferrari-Piquero · 2021 · Journal of Oncology Pharmacy Practice
64. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
    Takuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, Masanobu Saruta, Yusuke Yano, Takaya Ohno, Taizo Uchimoto, Wataru Fukuokaya, Takahiro Adachi, Shogo Yamazaki et al. · 2023 · Clinical Genitourinary Cancer
65. Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
    Ajami Gikandi, Susan N Chi, Kee Kiat Yeo, Allison Frances O'Neill, David Stephen Shulman, Steven G. DuBois, Natalie Bucheimer Collins · 2024 · Cancer Medicine
66. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2022 · Targeted Oncology
67. Nivolumab in non–small cell lung cancer: A novel case of an erythema annulare centrifugum–like eruption
    Polytimi Sidiropoulou, Themis Sgontzou, Ιωάννα Κωστάρα, Dimitrios Sgouros, B Theologi, Eftychia Zouridaki, Georgios Kontochristopoulos, Dimitris Rigopoulos, Alexander Stratigos · 2019 · JAAD Case Reports
68. Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients
    Kin-Sang Lau, Ronald Liu, Cheuk Cheuk Wong, Wai‐Kwan Siu, Kwok-Keung Yuen · 2019 · Annals of Palliative Medicine
69. Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis
    Yajun Zhang, Qian-Yu Tian, Caie Wang · 2024 · Frontiers in Oncology
70. Immune checkpoint inhibitor-related myocarditis in patients with lung cancer
    Wenli Cao, Sen Han, Panpan Zhang, Lan Mi, Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen et al. · 2025 · BMC Cancer
71. Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
    Jiří Blažek, Petr Hošek, Karolína Hrabcová, Monika Bratová, Juraj Kultan, Michal Hrnčiarik, Markéta Černovská, Petra Zemanová, Jana Krejčí, Leona Koubková et al. · 2023 · In Vivo
72. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
    Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina Charlotte Kähler, Nicole Kreuzberg et al. · 2024 · Frontiers in Immunology
73. Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
    Mario Giovanni Chilelli, Carlo Signorelli, Julio Rodrigo Giròn Berrìos, Angelo Onorato, Fabrizio Nelli, Agnese Fabbri, Francesca Primi, Eleonora Marrucci, Antonella Virtuoso, Marta Schirripa et al. · 2022 · Cancer Diagnosis & Prognosis
74. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1
    Mattia Brigida, Alessia Perricelli, Fausto Sposato, Maria Giovanna Spadafora, Angelo Pomillo, Sisto Milito · 2020 · Reviews on Recent Clinical Trials
75. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency
    Kei Sonehara, Kazunari Tateishi, Taro Hirabayashi, Taisuke Araki, Yuichi Ikuyama, Ryosuke Machida, Masayuki Hanaoka · 2021 · Case Reports in Oncology
76. Immune-related adverse events with immune checkpoint inhibitors
    Aya Hirata, Takeshi Saraya, Fumi Kobayashi, Akinari Noda, Kaori Aso, Sho Sakuma, Nozomi Kurokawa, Manami Inoue, Sunao Mikura, Miku Oda et al. · 2021 · Medicine
77. The dark side of immunotherapy: challenges facing the new hope in cancer treatment
    Eduard Teixidor, Joaquim Bosch‐Barrera · 2019 · Annals of Translational Medicine
78. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors
    Keitaro Shimozaki, Yasutaka Sukawa, Noriko Beppu, Isao Kurihara, Shigeaki Suzuki, Ryuichi Mizuno, Takeru Funakoshi, Shinnosuke Ikemura, Kai Tsugaru, Kazuhiro Togasaki et al. · 2020
79. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis
    Blake McKinley, Tanmayi Pai, Emily B. Wolf, Shenduo Li, Guilherme Sacchi de Camargo Correia, Yujie Zhao, Rami Manochakian, Yanyan Lou · 2024 · Frontiers in Oncology
80. Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
    Jarushka Naidoo, Douglas Buckner Johnson, Charlotte Doran, Yuexi Wang, Yan Zhang, Trong Kim Le, Sari D. Hopson, Brian Dreyfus, Lincy Subha Lal, Charmy Vyas et al. · 2024 · The Oncologist
81. Pulmonary Adverse Events in Cancer Immunotherapy: Case Studies of CT Patterns
    Giorgio Bocchini, Maria Chiara Imperato, Tullio Valente, Salvatore Guarino, Roberta Lieto, Candida Massimo, Emanuele Muto, Federica Romano, Mariano Scaglione, Giacomo Sica et al. · 2024 · Diagnostics
82. Testing Immune-Related Adverse Events in Cancer Immunotherapy
    Jocelyn R. Farmer · 2019 · Clinics in Laboratory Medicine
83. Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
    Evangelia Vlachou, Burles Avner Johnson, David James McConkey, Noah M. Hahn, Yuezhou Jing, Stephanie Russell, Daniel Stairiker, Antony Rosen, Livia A Casciola-Rosen, Jean H. Hoffman-Censits · 2025 · Cancer Research Communications
84. Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study
    Umair Mahmood, Eleni Josephides, Meenali M. Chitnis, Michael Skwarski, Spyridon Gennatas, Sharmistha Ghosh, James F. Spicer, Eleni M. Karapanagiotou, Tanya Ahmad, Martin David Forster et al. · 2025 · Cancers
85. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Tülay Kuş, Gökmen Aktaş · 2019 · Journal of Oncology Pharmacy Practice
86. Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
    Paolo Bossi, Luigi Lorini · 2021 · Dermatology Practical & Conceptual
87. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review
    Júlia de Almeida Santos Freitas, Maria Teresita Bendicho, Aníbal de Freitas Santos Júnior · 2023 · Journal of Oncology Pharmacy Practice
88. The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study
    Laure Vacher, Maureen Bernadach, Ioana Molnar, Judith Passildas, Pascale Dubray‐Longeras · 2024 · Health Science Reports
89. Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta
    Eduard Vrdoljak, Claude Magri, Marija Gamulin, Lidija Bošković, Tomislav Omrčen, Žarko Bajić, Tamás Dienes, Lajos Géczi · 2020 · Neoplasma
90. Immune checkpoint inhibitor–induced arthralgia is tightly associated with improved overall survival in cancer patients
    Ayaka Maeda, Kaoru Takase‐Minegishi, Yohei Kirino, Naoki Hamada, Yosuke Kunishita, Ryusuke Yoshimi, Akira Meguro, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima et al. · 2022 · Rheumatology
91. Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors
    Feifei Wei, Hiroyuki Takeda, Koichi Azuma, Yoshiro Nakahara, Yuka Igarashi, Kenta Murotani, Haruhiro Saito, Shuji Murakami, Tetsuro Kondo, Taku Kouro et al. · 2025 · Frontiers in Immunology
92. A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
    Atsuto Mouri, Hisao Imai, Satoshi Endo, Junichi Nakagawa, Kasumi Tsukamoto, Yuhei Kurata, Ou Yamaguchi, Kenji Masaki, Kosuke Hashimoto, Ayako Shiono et al. · 2025 · Cancer Medicine
93. Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
    Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato et al. · 2023 · Thoracic Cancer
94. Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer
    Kohdai Ueno, Kunihito Suzuki, KATSUMASA SAITO, Hajime Shinohara, Akinori Miura · 2024 · In Vivo
95. Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
    Panagiotis Theodorou Diamantopoulos, Aikaterini Gkoufa, Amalia N. Anastasopoulou, Panagiotis Kouzis, Georgios Lyrarakis, Georgios Kyriakakis, Helen J Gogas · 2025 · Cancer Medicine
96. Checkpoint inhibitor pneumonitis: Short review of literature and case report
    Romana Elisabeth Wass, David Lang, Andreas Horner, Bernd Lamprecht · 2021 · memo - Magazine of European Medical Oncology
97. Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study
    Françoise Lilly Difoum, Antoine Schernberg, Helene Vanquaethem, Hugo Picchi, Audrey Le Roy, Perrine Vuagnat, Carole Hélissey · 2022 · Cancer Reports
98. Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients
    Dan Tao, Haike Lei, Lisi Sun, Lulu Wang, Wei Zhou, Ying Wang, Yongzhong Wu · 2026 · BMC Cancer
99. The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients
    Ni Sun, Ru Li, Haiyi Deng, Qingyang Li, Jiaxi Deng, Yue Zhu, Wenwei Mo, Wenhui Guan, Minjuan Hu, Ming Liu et al. · 2024 · Frontiers in Oncology
100. Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer
     Mengyao Cai, Jiangqian Sun, Jingyi Wu, Ya Liu, Yuanyi Huang · 2025 · Frontiers in Oncology